Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (NYSE:ALC), the global eye care leader, has achieved certification as a Top Employer in Canada for 2025 by the Top Employers Institute. The recognition highlights Alcon Canada's excellence in key areas including People Strategy, Career Development, Rewards and Recognition, Purpose and Values, and Diversity & Inclusion.
The company's strengths include its comprehensive learning programs, leadership development initiatives, and commitment to sustainability, aiming for carbon neutrality by 2030. Alcon Canada's Head Office maintains ISO 14001:2015 Environmental Management System certification and demonstrates strong ethical business practices, including compliance with the Accessibility for Ontarians with Disabilities Act.
Alcon (NYSE: ALC) has received FDA approval for TRYPTYR (acoltremon ophthalmic solution) 0.003%, a first-in-class treatment for Dry Eye Disease (DED). The drug, which works as a TRPM8 receptor agonist, demonstrated significant efficacy in Phase 3 trials involving over 930 patients. Up to four times more TRYPTYR patients experienced increased natural tear production compared to the control group, with results visible as early as Day 1.
The treatment, administered as one drop per eye twice daily, addresses a significant market need, as approximately 38 million Americans suffer from DED, with less than 10% receiving prescription treatment. Alcon plans to launch TRYPTYR in the U.S. during Q3 2025.
[ "First-in-class TRPM8 receptor agonist showing rapid efficacy as early as Day 1", "Strong Phase 3 trial results with up to 4x more patients showing improved tear production vs. placebo", "Addresses large untapped market of 38 million U.S. patients with DED", "First prescription pharmaceutical treatment approval since Alcon became independent" ]Alcon has launched the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS), introducing breakthrough technologies for eye surgery. The platform features HYPERVIT 30K, the world's fastest vitrectomy probe at 30,000 cuts per minute, and UNITY 4D Phaco technology that delivers up to 2X faster nucleus removal with 41% less energy impact.
Key innovations include the UNITY Intelligent Fluidics system, UNITY 27 Gauge Portfolio with Dynamic Stiffener technology, and UNITY TetraSpot illuminated laser probe that reduces laser application time by up to three times. The system also features UNITY Intelligent Sentry, reducing post-occlusion surge volumes by 44%.
The product will begin shipping to Australia, Europe, Japan, and the U.S. from May onwards, with other markets following in Q3 2025 pending regulatory approvals.
Alcon (SIX/NYSE: ALC) has announced its upcoming Annual General Meeting (AGM) scheduled for May 6, 2025. The company proposes to elect Deborah Di Sanzo as a new Board member, bringing her extensive experience in digital, AI, and healthcare technology. Board member Raquel C. Bono, M.D., will not seek re-election after three years of service.
Key agenda items include the proposed cash dividend of CHF 0.28 per share, with an expected ex-dividend date of May 13, 2025 (SIX SIS shares) and May 14, 2025 (DTC shares). The agenda also covers the re-election of current board members, including F. Michael Ball as Chair, and votes on compensation for the Board and Executive Committee.
Alcon (NYSE: ALC) has announced the introduction of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in the U.S. The new IOL features proprietary ENLIGHTEN® NXT Optical technology, delivering 94% light utilization - the highest reported among trifocal IOLs - and half the light scatter compared to its predecessor.
Key improvements include more uninterrupted light distribution and a 16% increase in optical image contrast between distance and intermediate vision. The device will be commercially available in the U.S. in May 2025, featuring powers from +6.0 to +34.0 diopters. It will be the first presbyopia-correcting IOL available in the U.S. from Alcon in the single-use Clareon AutonoMe® preloaded delivery system.
Alcon (ALC) has acquired a majority stake in Aurion Biotech, a clinical-stage company developing advanced cell therapies for eye diseases. The key asset, AURN001, has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy Designations from the FDA for treating corneal edema.
Aurion will operate independently with Alcon's support to advance AURN001 into Phase 3 trials in the second half of 2025. The therapy can produce up to 1,000 doses from a single donor, addressing the global shortage of corneal tissue. Aurion has completed a Phase 1/2 clinical study (CLARA trial) with 97 subjects across the US and Canada.
The company has already achieved its first global commercial launch with Vyznova™ in Japan for treating bullous keratopathy. Dr. Arnaud Lacoste, formerly Chief Scientific Officer, has been appointed as Aurion's CEO.
Alcon (ALC) has received CE Mark approval for Clareon Vivity, an extended depth of focus (EDOF) intraocular lens (IOL) for cataract surgery. The commercial rollout in Europe will begin in early Q2 2025, with the AutonoMe automated pre-loaded delivery system available in Q3 2025.
The Clareon Vivity IOL combines Alcon's advanced Clareon material with Vivity's X-WAVE Technology, providing extended vision range from distance to functional near with minimal visual disturbances. Clinical outcomes show over 90% patient satisfaction rates, including successful results in patients with mild comorbidities such as AMD, glaucoma, and dry eye.
Key features include:
- One of the lowest levels of haze and glistenings compared to competitors
- STABLEFORCE Haptics for excellent axial and rotational stability
- Available in both UV-absorbing and blue light filtering options
- Reduced spectacle dependence while maintaining mesopic contrast sensitivity